NOVA SCOTIA RSV PROPHYLAXIS REQUEST FORM 2023-2024 (To be completed if the child lives outside of Halifax (formerly the Halifax Regional Municipality)

Date of Request (YYYY/MMM/DD)://	PATIENT REFERENCE NO
PATIENT INFORMATION	
Patient's Province of Residence:	Document initials of patient followed by the numerical
Patient Initials: First Initial	order:
Last Initial	(e.g. For Triplets enter as AB # 1, BB # 2, CB # 3)
□Male □Female	
Date of Birth/	Defined Nova Scotia RSV Season is January to May (ie the highest risk season when the annual RSV outbreak occurs). □ Initial Dose □ Subsequent Dose
Please indicate if infant is in a set of: □Twins □Triplets □ Quadruplets □ Parent/Guardian informed that the child's "non- identifying" demographic information will be shared with AstraZeneca Canada Inc. in Mississauga, Ontario for the purpose of obtaining the vaccine. The Nova Scotia Personal Health Information Act requires consent for release of any personal health information including demographics.	Dosing schedule: Palivizumab (Synagis) 15 mg/kg/dose intramuscularly once monthly beginning December 2023 through April 2024. Please order only one dose at a time for each patient Total # of 100 mg vials requested: Total # of 50 mg vials requested:
PHYSICIAN/NURSE PRACTIONER INFORMATION (All fields mandatory) Last Name:	Nova Scotia Health Authority Zone:
First Name :	Telephone: ()Ext:
Institution Name:	Fax: ()
Address:	Provincial Medical License No:
City:Province:	Certified Medical Specialty:
Postal Code:	Type of practice: □Community □Hospital
CRITERIA FOR CONSIDERATION OTHER CATEGORY	PRODUCT DELIVERY INFORMATION Shipping address (First dose):
☐Specific Medical Illness: Requires the following documentation before request can be sent for medical consultation:	n
 Letter from requesting physician providing medical justification for request and 	Shipping address (Subsequent doses, if different from above):
 Letter from infectious disease specialist or respirologist supporting the request 	
 Examples of children who could be considered high risk: severe combined immunodeficiency syndrome, severe hypotonia preventing adequate clearance of respiratory secretions, or severe chronic lung disease not due to prematurity. 	It is strongly recommended that Synagis® be delivered to a hospital pharmacy due to strict storage requirements. Palivizumab is sold on a "non-returnable" and "non-refundable" basis. Storage will be at: Pharmacy Physician Office Public Health

Patient Initials:	
	PATIENT REFERENCE NO
NDICATION FOR USE Date of Birth (YYYY/N	MMM/DD): / /
(Please select appropriate indication)	
Infants born prematurely at ≤ 32 weeks, 0 days gestation and aged ≤ 6 months WITH bronchopulmonary dysplasia/chronic lung disease	☐Children < 12 months of age with hemodynamically significant heart disease.
i.e. must be born on or after June 1, 2023.	
□ Infants born prematurely at ≤ 32 weeks, 0 days gestation and aged ≤ 6 months WITHOUT bronchopulmonary dysplasia/chronic lung disease i.e. must be born on or after June 1, 2023. Please record the EXACT gestational age at birth of this infant: weeksdays	□Children < 24 months of age with bronchopulmonary dysplasia/chronic lung disease AND who have required oxygen and/or medical therapy within the 6 months preceding the RSV season (June-November 2023). Age: □≤1 year old □Between 1 and 2 years old
MPORTANT	
Please fax or email all of this completed request fo 397-2357 OR enrollment@AZInfantPSP.ca	rm to: AstraZeneca's Synagis Care Coordinator at 1-833-
All RSV request forms submitted to AstraZeneca's Synagis Car number (entered on forms) and also to the IWK Health at 902-4	e Coordinator will be faxed back to the requesting physician's fax 70-7846.
Form completed by :	